胰高血糖素样肽-1（GLP-1）受体激动剂的使用与手术患者发生肺误吸的风险
Glucagon-like-peptide-1 (GLP-1) receptor agonist use and the risk of pulmonary aspiration in patients undergoing surgery.
作者信息
Wright Jason D, Chen Ling, Xu Xiao, Hur Chin, Matsuo Koji, Elkin Elena B, Hershman Dawn L
机构信息
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, New York State, USA.
Herbert Irving Comprehensive Cancer Center, New York, New York State, USA.
出版信息
Int J Surg. 2025 Jun 1;111(6):4090-4093. doi: 10.1097/JS9.0000000000002425. Epub 2025 May 12.
Glucagon-like-peptide-1 (GLP-1) receptor agonists are approved for the treatment of type II diabetes mellitus and obesity. These agents slow gastric emptying and may increase the risk of pulmonary aspiration, particularly in patients undergoing elective surgery. We used a claims database to examine the association between perioperative GLP-1 receptor agonist use and the risk of pulmonary aspiration. A total of 392 065 patients including 15 745 (4.0%) who used GLP-1 receptor agonist who underwent elective surgery were identified. The rate of pulmonary aspiration was 0.8% in those who received GLP-1 receptor agonists versus 0.7% in those who had not ( P = 0.61). After adjusting for other risk factors for aspiration, there was no association between GLP-1 agonist use and aspiration (OR = 1.07; 95% CI, 0.85-1.34).
胰高血糖素样肽-1（GLP-1）受体激动剂已被批准用于治疗2型糖尿病和肥胖症。这些药物会减缓胃排空，并可能增加肺误吸的风险，尤其是在接受择期手术的患者中。我们使用一个索赔数据库来研究围手术期使用GLP-1受体激动剂与肺误吸风险之间的关联。共识别出392065例接受择期手术的患者，其中15745例（4.0%）使用了GLP-1受体激动剂。接受GLP-1受体激动剂的患者肺误吸发生率为0.8%，未使用者为0.7%（P = 0.61）。在对其他误吸风险因素进行校正后，使用GLP-1激动剂与误吸之间无关联（OR = 1.07；95%CI为0.85-1.34）。
Zotero 插件